Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Biotie of Turku, Finland to acquire neurology and immunology focused pharmaceutical company elbion


October 24, 2008 - Biotie Therapies has today entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nervous system (addiction, psychotic disorders) and inflammatory diseases (e.g. rheumatoid arthritis, psoriasis and inflammatory diseseas of the respiratory system). elbion GmbH will become a wholly-owned subsidiary of Biotie.

'Bringing together the outstanding pharmaceutical development capabilities and strong clinical pipelines of both companies will create a European leader in the CNS and inflammation market,' says Mr. Juha Jouhki, the Chairman of Biotie. Mr Luc Philips, the Chairman of elbion NV stated that 'this business combination is a unique opportunity to combine complementary programs and capabilities with sufficient financial means to reach key value inflection points'.

The current CEO of Biotie Timo Veromaa will continue as the CEO of the new entity. Elbion's CEO, Bernd Kastler will join the Board of Biotie, along with current elbion Board members Ann Hanham and Christoph Schröder. The company will operate out of its two locations in Turku, Finland and Radebeul, Germany.

After the merger, Biotie will have a broad range of innovative drug candidates at different stages of clinical and pre-clinical development. Of the new additions to the pipeline, ELB353 is an orally available selective anti-inflammatory drug which has already completed phase I clinical testing. Buprenorphine Depot is a next generation proprietary formulation of the most widely used drug for the treatment of opioid dependence. In addition, Biotie gains access to a world-class drug discovery platform focussed on central nervous system and inflammatory diseases. Combined with Biotie's existing clinical stage development projects, including Nalmefene, which is in phase III clinical development for alcohol addiction, and Biotie's VAP-1 fully human monoclonal antibody drug for the treatment of inflammatory diseases, the combined product pipeline represents a compelling range of new drugs for diseases with high unmet medical need.

The combined company has validated the commercial potential of several of its development programs by gaining top-tier pharmaceutical companies, such as Roche, Wyeth and Lundbeck as collaboration partners. elbion GmbH has entered into a licensing and collaboration agreement for the development of PDE10-inhibitors for psychotic disorders with Wyeth, and Biotie has a licensing agreement with Lundbeck for the development of Nalmefene. These and further collaborations and license agreements have potential to generate significant revenues in the future.

Existing elbion NV investors Burrill & Company, TVM Capital, and AGF Private Equity have committed to invest into Biotie concomitantly with the transaction. After completion of the transaction, Biotie will have a total of approximately EUR 27 million in cash.

Biotie reported revenues of EUR 4.0 million for the first three quarters of 2008 and a net loss of EUR 3.8 million. On a pro-forma basis, the combined entity would have had revenues of EUR 6.6 million and would have incurred a loss of EUR 5.3 million in the first three quarters of 2008.

The transaction is subject to shareholder approval of both companies and is expected to close on 14 November 2008.


For further information:

BayTech Venture Capital
Dr. Heiko Ott
Investment Manager
Theatiner Str. 7
80333 München
+49 (0) 89 287009 0
Heiko.Ott@baytechventure.com


Publisher Contact Information:

BayTech Venture Capital
+49 (0) 89 287009 0
Heiko.Ott@baytechventure.com

Company profile of BayTech Venture Capital
Past press releases of BayTech Venture Capital.

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.